About

Manifold Bio focuses on creating precision biologics for the pharmaceutical industry. Their main product is an in vivo drug design platform, which allows for drug testing within living organisms rather than in laboratory settings. This platform utilizes mCodes™ technology, a unique protein barcoding system that enables the simultaneous study of multiple proteins in one experiment. This capability is especially beneficial for testing complex biologics, which are large molecule drugs derived from living organisms. Unlike other companies, Manifold Bio's approach to drug design is centered around in vivo testing, making it the first of its kind globally. The company's goal is to expand their platform and collaborate with other pharmaceutical companies to develop new therapeutics.

Simplify's Take

What believers are saying

• Raised $40M in Series A funding, indicating strong market interest.
• Major investors like Tencent and Horizons Ventures show confidence in their innovation.
• Their technology addresses the in vivo testing bottleneck in drug development.

What critics are saying

• Emerging competition in protein barcoding could threaten their market position.
• Rapid AI advancements may outpace their current platform capabilities.
• Regulatory challenges could delay multiplexed in vivo testing approvals.

What makes Manifold Bio unique

• Manifold Bio's mCodes™ technology enables multiplexed protein analysis in vivo.
• Their platform allows simultaneous testing of multiple molecules in living systems.
• They are pioneering in vivo biologics design, a first in the pharmaceutical industry.

Help us improve and share your feedback! Did you find this helpful?

YesNo